Your browser doesn't support javascript.
loading
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.
Anderson, Kristin G; Braun, David A; Buqué, Aitziber; Gitto, Sarah B; Guerriero, Jennifer L; Horton, Brendan; Keenan, Bridget P; Kim, Teresa S; Overacre-Delgoffe, Abigail; Ruella, Marco; Triplett, Todd A; Veeranki, Omkara; Verma, Vivek; Zhang, Fan.
Afiliación
  • Anderson KG; Department of Microbiology, Immunology and Cancer Biology, Obstetrics and Gynecology, Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, USA kristin.anderson@virginia.edu.
  • Braun DA; University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia, USA.
  • Buqué A; Center of Molecular and Cellular Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.
  • Gitto SB; Department of Radiation Oncology, Weill Cornell Medical College, New York, New York, USA.
  • Guerriero JL; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Horton B; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Keenan BP; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Kim TS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Overacre-Delgoffe A; Department of Surgery, University of Washington, Seattle, Washington, USA.
  • Ruella M; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Triplett TA; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Veeranki O; Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Verma V; Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas, USA.
  • Zhang F; Medical Affairs and Clinical Development, Caris Life Sciences Inc, Irving, Texas, USA.
J Immunother Cancer ; 11(6)2023 06.
Article en En | MEDLINE | ID: mdl-37399356
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos